Public Science, Private Cures, Captive Regulator

The 1980 Bayh-Dole Act made a quiet structural decision with enormous consequences: it allowed private companies and universities to patent inventions derived from federally-funded research. Before 1980, the government owned those patents and licensed them broadly. After 1980, the taxpayer-funded discovery becomes a corporate monopoly.

The mechanism is not subtle once you trace a drug. Sofosbuvir — the breakthrough hepatitis C cure sold by Gilead as Sovaldi — emerged from NIH-funded research at Emory University, receiving $60.9 million in direct and indirect NIH funding before Gilead acquired the developing company (Pharmasset) for $11.2 billion in 2012. Gilead then priced the resulting drug at $1,000 per pill — $84,000 for a standard course. Medicare and Medicaid spent $8.2 billion on it in the eighteen months following approval. The same drug manufactured under voluntary license sells for approximately $300 in India.

Remdesivir — Gilead's COVID-19 antiviral — benefited from $6.5 billion in NIH-funded basic research, plus $34.5 million from the Department of Defense and direct BARDA funding. Gilead priced the resulting treatment at $3,120 per course for US insurers — approximately triple the cost in other developed nations.

The mRNA COVID-19 vaccines provide the starkest illustration. Moderna received nearly $10 billion in US taxpayer funding plus approximately $1 billion from BARDA. NIH scientists claimed co-inventorship on core vaccine patents. Moderna refused to recognize the claims. The dispute was partially resolved with a $400 million payment to NIH — against vaccine sales in the billions. The technology that stopped a pandemic was built with public money and monetized as a private asset.

Forty-five years after Bayh-Dole, the government has never once exercised "march-in rights" — its statutory authority to override exclusive patents on publicly-funded inventions when price or availability fails the public interest. The right exists on paper. The captured apparatus has never used it.

Patent evergreening is the industry's method for converting a 20-year monopoly into a decades-long monopoly. The core drug patent expires. The company files secondary patents on delivery devices, salt formulations, dosing schedules, and manufacturing processes — each one a new barrier to generic competition.

Humira (adalimumab, AbbVie) is the case study. The core patent on the world's top-selling drug expired in 2016. AbbVie filed 247 US patent applications — 132 granted — creating what researchers at I-MAK call a "patent thicket." 90% of those filings cameafter FDA approval in 2002. 85 patents were filed between 2013 and 2016 — the run-up to core patent expiry. Biosimilar competitors were kept off the US market until 2023 — seven years after the original patent expired. AbbVie's revenue during those seven additional years of monopoly: tens of billions.

Insulin — a molecule discovered in 1921 — has been continuously re-patented for a century. A 2023 PLOS Medicine study found the three dominant insulin products carry median market protections of over 30 years: Lantus (32.9 years), Novolog (32.3 years), Novolog 70/30 (30.9 years). Over 100 post-approval patents were filed across major insulin products, with 63% of device patents related to delivery systems — pens and auto-injectors — extending exclusivity by a median of 6+ additional years.

Gilead's tenofovir switch (TDF to TAF) demonstrates that evergreening can also involve deliberate delay of an improvement. Gilead developed tenofovir alafenamide (TAF) simultaneously with tenofovir disoproxil fumarate (TDF) in 2001. Internal documents show Gilead halted TAF development in 2004 and restarted it in 2011 — timed precisely to when TDF's patents were expiring in 2017. The company had data from 2001 showing TAF's superior kidney and bone toxicity profile. It withheld the safer drug for a decade to preserve TDF revenue. Within three years of TAF approval, 80% of TDF users had switched. Gilead's patent clock reset by five years.

The structural critique is precise: evergreening is not innovation. It is the deliberate use of patent law — lobbied for by the same companies that exploit it — to prevent the competitive market the patent system was designed to produce.

The Prescription Drug User Fee Act (PDUFA), enacted in 1992, established a structural conflict at the center of US drug regulation: the pharmaceutical industry pays fees to fund FDA drug reviews. By fiscal year 2024, those fees totaled $1.36 billion annually. The FDA's drug review division is substantially funded by the corporations whose applications it evaluates.

The user fee arrangement comes with performance goals negotiated between the FDA and the industry. The practical effect is an FDA that has been conditioned to view approval speed as a success metric — with consequences for the rigor of safety evaluation. The agency's largest single revenue source has an institutional interest in yes answers.

The revolving door compounds this. A Stanford Law Review analysis of FDA commissioners from 2006 to 2019 found 9 of 10 went to work for pharmaceutical companies after leaving the agency. Approximately 38% of FDA employees who departed during that period moved to industry positions. FOIA-obtained records revealed ethics staff advising departing officials on how to conduct "behind-the-scenes" lobbying in ways that technically complied with post-employment restrictions while achieving the same effect.

Advisory committees — the expert panels that make formal drug approval recommendations — compound the structural capture. A Milbank Quarterly analysis found that 73% of 221 FDA drug advisory meetings had at least one member with financial conflicts of interest; 28% of voting members had direct financial ties to the sponsoring company. Members with financial interest in the sponsor were significantly more likely to vote for approval. Despite this, only 1% of conflicted panelists were recused. The remaining 99% voted.

The FDA's stated mission is protecting public health. Its structural funding relationship, its personnel pipeline, and its advisory system are all oriented around the commercial success of the companies it nominally oversees. This is not corruption at the margins. It is capture by design.

When pharmaceutical companies justify $84,000 drug prices, they invoke research and development costs. The argument is central to their political and legal defense. It deserves examination against the record.

A JAMA analysis by Schwartz and Woloshin covering the period 1997–2016 found US pharmaceutical companies spent more on marketing and administration than on research for much of the period studied. A broader analysis of the 15 largest pharmaceutical companies found they spent $800 billion more on marketing and administration than on research over a two-decade window.

The Senate Finance Committee investigation of Sovaldi — Gilead's hepatitis C drug — found that internal pricing decisions were made with minimal consideration of R&D costs. Gilead's own documents showed pricing was explicitly driven by revenue maximization and anticipation of public relations blowback — not by recouping research investment. The R&D, as documented above, had largely been funded by NIH and done by Pharmasset before Gilead acquired the company.

Direct-to-consumer advertising — legal only in the US and New Zealand — adds another layer. The US pharmaceutical industry spends billions annually on television, digital, and print advertising encouraging patients to ask their doctors for specific brand-name drugs. These costs flow through the price of prescriptions. The patient pays for the ad that persuaded them to request the drug.

The pharmaceutical lobby is one of the largest in Washington. OpenSecrets data shows the industry consistently ranks among the top spenders on federal lobbying and campaign contributions — funds that purchase the patent law, trade agreements, and pricing regulations that produce the margins that are then justified as necessary for R&D. The R&D argument is circular: we need the profits to fund research that we obtain the rights to by lobbying for laws that generate the profits.

Insulin was discovered in 1921 by Frederick Banting and Charles Best at the University of Toronto. They sold the patent to the University of Toronto for $1 each. Banting's stated reasoning: the discovery belonged to humanity. For several decades, generic insulin was inexpensive and widely accessible.

Beginning in the 1990s, the three dominant insulin manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — began systematically replacing older, off-patent insulin formulations with new analog versions: slightly modified molecules protected by fresh patents. The older formulations were phased out or discontinued. Patients were switched to the newer, patent-protected versions. Each switch reset the exclusivity clock.

The price consequences were documented by a 2021 Senate Finance Committee investigation. Humalog — Eli Lilly's insulin — increased in price by 585%, from $35 to $234 per vial, between 2001 and 2015. The three manufacturers practiced what the committee called "shadow pricing" — raising prices within hours of each other, in lock-step, without the price competition that competitive markets produce. The investigation found no evidence of collusion in the legal sense, but documented a market structure that produced identical price behavior across three nominally competing firms.

The same insulin vial that costs $300 or more in the US costs approximately $44 in Canada and a fraction of that in France. The molecule is identical. The manufacturing process is identical. The price differential is a regulatory construction — built by the same lobbying apparatus documented throughout this thread.

People are dying from this price structure. The Right Care Alliance documented at least 14 deaths from insulin rationing in the US between 2017 and 2020 — people who stretched or skipped doses because they could not afford to refill their prescriptions. Among the documented deaths: Alec Smith, 26, Minnesota, June 2017; Jesse Lutgen, 32, February 2018; Jeremy Crawford, 39, Dallas, August 2019. Approximately 1.3 million Americans ration insulin annually.

Banting donated the patent in 1923 so that no one would die for lack of access. The patent regime his successors built ensures that people do.

The EpiPen saga is not an outlier. It is the template — the clearest single demonstration of how the pharmaceutical pricing apparatus operates when nothing goes wrong from the industry's perspective.

Mylan acquired the EpiPen in 2007. The epinephrine auto-injector had been available for decades; the generic drug inside it — epinephrine — costs pennies to manufacture. Mylan did not develop the device and did not meaningfully improve it. The acquisition gave Mylan a distribution network and a market position. Between 2009 and 2016, Mylan increased the price of a two-pack from $103.50 to $608.61 — a 490% increase.

During the same period, CEO Heather Bresch's total compensation rose from $2.5 million in 2007 to $19 million in 2015 — a 7.6× increase. Her father was Senator Joe Manchin of West Virginia. No conflict of interest was formally adjudicated.

Mylan also ran a school nurse lobbying campaign — funding advocacy for legislation that required schools to stock EpiPens and that provided federal grants for school purchases. The company manufactured the perceived need, funded the procurement infrastructure, and set the price. The Justice Department investigated. In August 2017, Mylan paid a $465 million settlement — resolved through a non-prosecution agreement, with no admission of wrongdoing, and no criminal charges against any executive.

The EpiPen playbook — acquire a necessity, raise the price to extraction levels, lobby to expand mandated use, settle any investigation for a fraction of the profits, and continue — is replicated across dozens of off-patent drugs annually. The settlement amount is a cost of business. The pricing structure is intact. The executives are not in prison.